<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7102570\results\search\drug\results.xml">
  <result pre="Guanosine, inosine, and AICAR are biosynthesized in the body, and" exact="ribavirin" post="and ribosyl favipiravir are synthesized nucleoside analogues. They have"/>
  <result pre="with efficacy, but they did not exceed the efficacy of" exact="acyclovir" post="in animals. Approximately 30,000 compounds synthesized in the company"/>
  <result pre="of interferon (IFN) and cytokines that induce cyclooxygenase expression and" exact="prostaglandin E2" post="production and cause fever. The effects of interferon and"/>
  <result pre="1998; Kurokawa, Brown, Kagawa, &amp;amp; Shiraki, 2003). Cinnamyl compounds and" exact="clarithromycin" post="increase the levels of IL-12 on day 2 and"/>
  <result pre="influenza-infected mice by decreasing the serum IL-1 level. In contrast," exact="aspirin" post="suppresses fever by inhibiting hypothalamic cyclooxygenase activity and prostaglandin"/>
  <result pre="contrast, aspirin suppresses fever by inhibiting hypothalamic cyclooxygenase activity and" exact="prostaglandin E2" post="production without affecting the high level of IL-1 (Kurokawa,"/>
  <result pre="we have experience in conducting a pharmacological study for a" exact="famciclovir" post="approval application in Japan, the efficacy and validation studies"/>
  <result pre="infected cell and proceeds to the next round of infection." exact="Amantadine" post="blocks uncoating by inhibiting acidification mediated by the M2"/>
  <result pre="site, and no new RNA is generated in the cell." exact="Baloxavir marboxil" post="prevents Cap-snatching, and the viral mRNA is not produced,"/>
  <result pre="genomic RNA serves as a rich source of resistant viruses." exact="Amantadine" post="inhibits the uncoating of influenza A in late endosomes,"/>
  <result pre="and viral RNA does not replicate in the infected cells." exact="Amantadine" post="inhibits only influenza A and not B. However, influenza"/>
  <result pre="infection. NAIs are currently the main choice of anti-influenza drugs." exact="Baloxavir marboxil" post="(baloxavir, XofluzaÂ®) is a selective inhibitor of influenza Cap-dependent"/>
  <result pre="different from the range of 0.014â€&quot;0.55Â Î¼g/mL in medium without" exact="adenosine" post="and guanosine and 10Â Î¼g/mL, respectively (Furuta et al.,"/>
  <result pre="strand cannot be completed. In contrast, the anti-RNA virus drug" exact="ribavirin" post="is incorporated into the replicating strand, which further elongates"/>
  <result pre="accumulates mismatched nucleotides at the incorporated sites. Base pairing with" exact="ribavirin" post="in the complementary strand during replication, transcription, and translation"/>
  <result pre="and infectious viruses with mutations in viral RdRp that affect" exact="ribavirin" post="incorporation are produced, drug-resistant viruses can be selected in"/>
  <result pre="et al., 2012; Vanderlinden et al., 2016). B. Lethal mutagenesis" exact="Ribavirin" post="is incorporated into the elongating RNA strand, and viral"/>
  <result pre="to elongate until completion. Next, the RNA strand with multiple" exact="ribavirin" post="incorporation sites further incorporates ribavirin or serves as mRNA"/>
  <result pre="the RNA strand with multiple ribavirin incorporation sites further incorporates" exact="ribavirin" post="or serves as mRNA for viral protein synthesis. The"/>
  <result pre="serves as mRNA for viral protein synthesis. The incorporation of" exact="ribavirin" post="in the viral RNA causes the mismatch of base"/>
  <result pre="(Daikoku et al., 2017; Daikoku, Yoshida, Okuda, &amp;amp; Shiraki, 2014)." exact="Ribavirin" post="is known to cause lethal mutagenesis, as shown in"/>
  <result pre="known to cause lethal mutagenesis, as shown in Fig. 5." exact="Ribavirin" post="is incorporated into the elongating RNA strand, resulting in"/>
  <result pre="(Jin et al., 2013; Sangawa et al., 2013). Favipiravir-RTP and" exact="ribavirin" post="TP inhibit the RdRp activity in a dose-dependent manner,"/>
  <result pre="and a low IC50 (0.14Â Î¼M). On the other hand," exact="ribavirin" post="induces competitive inhibition with GTP, and incorporation results in"/>
  <result pre="incorporate labeled GTP without stopping at the incorporation site. Thus," exact="ribavirin" post="has a high IC50 value (2.4Â Î¼M) because its"/>
  <result pre="6.3 Mutation due to chain termination and proofreading activity by" exact="acyclovir" post="Proofreading activity mediated by enzymes such as the 3â€²-5â€²"/>
  <result pre="virus DNA and prevents viral DNA synthesis. However, the incorporated" exact="acyclovir" post="is removed by the proofreading activity of viral DNA"/>
  <result pre="1999; Shimada et al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993)." exact="Penciclovir" post="(famciclovir) and ganciclovir (valganciclovir), which are guanosine analogues, function"/>
  <result pre="al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993). Penciclovir (famciclovir) and" exact="ganciclovir" post="(valganciclovir), which are guanosine analogues, function as an anti-herpes"/>
  <result pre="activity causes a lower mutation frequency in subjects treated with" exact="penciclovir" post="and ganciclovir than in subjects treated with acyclovir. If"/>
  <result pre="a lower mutation frequency in subjects treated with penciclovir and" exact="ganciclovir" post="than in subjects treated with acyclovir. If favipiravir induces"/>
  <result pre="of favipiravir into viral RNA followed by elongation, similar to" exact="ribavirin" post="or acyclovir (Fig. 5). Favipiravir is unlikely to induce"/>
  <result pre="into viral RNA followed by elongation, similar to ribavirin or" exact="acyclovir" post="(Fig. 5). Favipiravir is unlikely to induce mismatches upon"/>
  <result pre="mismatched transition mutations without treatment with mutagens such as ribavirin." exact="Ribavirin" post="reduces GTP levels by inhibiting inosine monophosphate dehydrogenase, but"/>
  <result pre="has a similar mechanism of action to the antiherpesvirus drug" exact="acyclovir" post="and has the property of not producing a resistant"/>
  <result pre="of deoxyribonucleotidesAmerican Journal of Physiology. Cell Physiology2812001C1776C178411698235 BeisI.NewsholmeE.A.The contents of" exact="adenine" post="nucleotides, phosphagens and some glycolytic intermediates in resting muscles"/>
  <result pre="herpes simplex virus with mutation of homopolymeric guanosine strings during" exact="acyclovir" post="therapyJournal of Dermatological Science82201616016526917345 DaikokuT.YoshidaY.OkudaT.ShirakiK.Characterization of susceptibility variants of"/>
  <result pre="respiratory tract of miceActa Virologica53200923324019941386 HawmanD.W.HaddockE.Meade-WhiteK.WilliamsonB.HanleyP.W.RosenkeK. â€¦FeldmannH.Favipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
  <result pre="South East Asia and South AfricaAntiviral Research832009909319501261 IdaM.KageyamaS.SatoH.KamiyamaT.ToyomotoT.OzakiT. â€¦ShirakiK.Characterization of" exact="acyclovir" post="susceptibility and genetic stability of varicella-zoster viruses isolated during"/>
  <result pre="acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during" exact="acyclovir" post="therapyJournal of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. â€¦ShirakiK.Emergence of resistance to"/>
  <result pre="acyclovir therapyJournal of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. â€¦ShirakiK.Emergence of resistance to" exact="acyclovir" post="and penciclovir in varicella-zoster virus and genetic analysis of"/>
  <result pre="of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. â€¦ShirakiK.Emergence of resistance to acyclovir and" exact="penciclovir" post="in varicella-zoster virus and genetic analysis of acyclovir-resistant variantsAntiviral"/>
  <result pre="in influenza virus-infected miceChem Pharm Bull (Tokyo)461998144414479775439 KurosakiK.MiwaN.YoshidaY.KurokawaM.KurimotoM.EndoS.ShirakiK.Therapeutic basis of" exact="vidarabine" post="on adenovirus-induced haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. â€¦YuH.Global"/>
  <result pre="of arenavirus hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of" exact="acyclovir" post="and vidarabine on the replication of varicella-zoster virusAntiviral Research652005495515652971"/>
  <result pre="hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of acyclovir and" exact="vidarabine" post="on the replication of varicella-zoster virusAntiviral Research652005495515652971 MoriH.ShirakiK.KatoT.HayakawaY.YamanishiK.TakahashiM.Molecular analysis"/>
  <result pre="Research1052014172124583123 OestereichL.RiegerT.LudtkeA.RuibalP.WurrS.PallaschE. â€¦GuntherS.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, Immunocompetent mouse model of Lassa feverThe"/>
  <result pre="(H1N1) infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. â€¦Emory Serious Communicable DiseasesU.Favipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa feverClinical Infectious"/>
  <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Research1042014849224486952 ShimadaY.SuzukiM.ShirasakiF.SaitoE.SogoK.HasegawaM. â€¦ShirakiK.Genital herpes due to acyclovir-sensitive herpes"/>
  <result pre="for herpesvirus infection: Towards practical application for treating herpes zosterDrugs" exact="Today" post="(Barc)53201757358429451274 ShirakiK.Antiviral drugs against AlphaherpesvirusAdvances in Experimental Medicine and"/>
  <result pre="of drug-resistant mutants of varicella-zoster virus - cross resistance of" exact="acyclovir" post="resistant mutants with phosphonoacetic acid and bromodeoxyuridineBiken Journal26198317236312958 ShirakiK.OginoT.YamanishiK.TakahashiM.Immunochemical"/>
  <result pre="with AIDSJournal of Virology671993102410338380452 TanakaT.KamiyamaT.DaikokuT.TakahashiK.NomuraN.KurokawaM.ShirakiK.T-705 (Favipiravir) suppresses tumor necrosis factor" exact="alpha" post="production in response to influenza virus infection: A beneficial"/>
  <result pre="(IL)-12 level in the airway of mice administered orally with" exact="clarithromycin" post="or intranasally with IL-12 results in alleviation of influenza"/>
  <result pre="Jan 1434635531309975 VanderlindenE.VranckenB.Van HoudtJ.RajwanshiV.K.GillemotS.AndreiG. â€¦NaesensL.Distinct effects of T-705 (Favipiravir) and" exact="ribavirin" post="on influenza virus replication and viral RNA synthesisAntimicrobial Agents"/>
  <result pre="patients with influenza virus infectionJ Infect Dis2019jiz65610.1093/infdis/jiz65631822885 WestoverJ.B.SefingE.J.BaileyK.W.Van WettereA.J.JungK.H.DagleyA. â€¦GowenB.B.Low-dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
 </snippets>
</snippetsTree>
